MAPT and amyloidosis: Akin to the use of biomarkers to quantify amyloid burden, the tau landscape is rapidly evolving, with ultrasensitive immunoassays allowing the reliable measurement of tau biomarkers in blood, while second-generation tau-PET tracers are being developed [108].